Subscribe
Be the first with the news that moves the market- Universal Ibogaine has appointed Nick Karos as CEO on an interim basis, effective immediately.
- Mr. Karos is a seasoned financier whose career has included senior roles with several US investment banks
- Mr. Karos remains a short-listed candidate for the permanent position
- Universal Ibogaine is a life sciences company researching medicalized ibogaine-centred addiction care
- Universal Ibogaine Inc. (IBO) opened trading at C$0.14 per share
Universal Ibogaine (IBO) has appointed Nick Karos as CEO on an interim basis, effective immediately.
Mr. Karos is based in Los Angeles, USA, and is a seasoned financier. His career includes senior roles with several US investment banks and most recently as CEO of Private Trading Group, which has provided business development and capital raising services for several successful start-up ventures.
Nick Karos sat down with Caroline Egan to discuss the appointment.
“I’m very excited to work with the talented partners at UI to move towards our goal of conducting clinical trials with Health Canada. Universal Ibogaine’s goal is to transform the addiction treatment model using ibogaine as the cornerstone of our new addiction treatment protocol. Addiction is a disease that affects society like none other, and we believe our ground-breaking protocol will give patients and families a better path towards long-term recovery.”
The board will immediately begin an executive search process for selecting a new CEO. Mr. Karos remains a short-listed candidate for the permanent position.
Universal Ibogaine is a life sciences company with a mission to research and deliver medicalized ibogaine-centred addiction care.
Universal Ibogaine Inc. (IBO) opened trading at C$0.14 per share.
